Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Inflammatory Biomarkers in Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), and HIV/HCV Coinfection. by Hanberg, Jennifer S et al.
UCLA
UCLA Previously Published Works
Title
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Inflammatory 



















eScholarship.org Powered by the California Digital Library
University of California
M A J O R  A R T I C L E
NLR and PLR in HIV/HCV • ofid • 1
Open Forum Infectious Diseases
 
Received 10 May 2019; editorial decision 14 July 2019; accepted 24 July 2019.
Correspondence: A.  C. Justice,  MD,  PhD, PI, Veterans Aging Cohort Study, Professor of 
Medicine VA Connecticut Healthcare System, 950 Campbell Ave., West Haven, CT 06516 (amy.
justice2@va.gov).
Open Forum Infectious Diseases®
Published by Oxford University Press on behalf of Infectious Diseases Society of America 2019. 
This work is written by (a) US Government employee(s) and is in the public domain in the US.
DOI: 10.1093/ofid/ofz347
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte 
Ratios as Prognostic Inflammatory Biomarkers in Human 
Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), 
and HIV/HCV Coinfection
Jennifer S. Hanberg,1,2 Matthew S. Freiberg,3 Matthew B. Goetz,4,5 Maria C. Rodriguez-Barradas,6,7 Cynthia Gibert,8 Kris Ann Oursler,9,10 Amy C. Justice,1,2,  
Janet P. Tate,1,2 and the VACS Project Team
1Department of Medicine, Yale University School of Medicine, New Haven, Connecticut; 2VA Connecticut Healthcare System, West Haven; 3Department of Medicine and Epidemiology, Vanderbilt 
University School of Medicine, Nashville, Tennessee; 4Division of Infectious Diseases, University of California, David Geffen School of Medicine, Los Angeles; 5Greater Los Angeles VA Healthcare 
Center, California; 6Department of Medicine and Infectious Disease, Baylor College of Medicine, Houston, Texas; 7Michael E. DeBakey VA Medical Center, Houston, Texas; 8Division of Infectious 
Diseases and Medicine, George Washington University, School of Medicine and Health Sciences, Washington, District of Columbia; 9Department of Medicine, Virginia Tech Carilion School of 
Medicine, Salem; 10University of Maryland School of Medicine, Baltimore
Background. Inflammation in human immunodeficiency virus (HIV)-infected patients is associated with poorer health out-
comes. Whether inflammation as measured by the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) 
adds information to existing prognostic indices is not known.
Methods. We analyzed data from 2000 to 2012 in the Veterans Aging Cohort Study (VACS), overall and stratified by HIV/hep-
atitis C virus status (n = 89 786). We randomly selected a visit date at which all laboratory values of interest were available within 
180 days; participants with HIV received at least 1 year of antiretroviral therapy. We followed patients for (1) mortality and (2) hepatic 
decompensation (HD) and analyzed associations using Cox regression, adjusted for a validated mortality risk index (VACS Index 2.0). 
In VACS Biomarker Cohort, we considered correlation with biomarkers of inflammation: interleukin-6, D-dimer, and soluble CD-14.
Results. Neutrophil-to-lymphocyte ratio and PLR demonstrated strong unadjusted associations with mortality (P < .0001) and 
HD (P < .0001) and were weakly correlated with other inflammatory biomarkers. Although NLR remained statistically independent 
for mortality, as did PLR for HD, the addition of NLR and PLR to the VACS Index 2.0 did not result in significant improvement in 
discrimination compared with VACS Index 2.0 alone for mortality (C-statistic 0.767 vs 0.758) or for HD (C-statistic 0.805 vs 0.801).
Conclusions. Neutrophil-to-lymphocyte ratio and PLR were strongly associated with mortality and HD and weakly correlated 
with inflammatory biomarkers. However, most of their association was explained by VACS Index 2.0. Addition of NLR and PLR to 
VACS 2.0 did not substantially improve discrimination for either outcome.
Keywords.  HCV; hepatic decompensation; inflammation; NLR; PLR.
Human immunodeficiency virus (HIV) infection is associated 
with chronic proinflammatory states, even in patients receiving 
antiretroviral therapy (ART) [1, 2]. Inflammation in HIV, even 
when viral loads are low or undetectable, is associated with wors-
ened outcomes including mortality, development of acquired 
immunodeficiency syndrome, and cirrhosis (in hepatitis C virus 
[HCV] coinfection) [3–8]. Most inflammatory biomarkers are 
not measured in standard practice and may be expensive or 
impractical to monitor routinely. Two established markers of 
subclinical inflammation, the neutrophil-to-lymphocyte ratio 
(NLR) and platelet-to-lymphocyte ratio (PLR), are easily deter-
mined from a complete blood count.
Neutrophil-to-lymphocyte ratio and PLR are associated with 
mortality in populations with and without HIV [9–13]. Platelet-
to-lymphocyte ratio is also associated with hepatic fibrosis in 
HCV [14, 15]. However, the clinical impact of these biomarkers 
is not clear. If they are useful for prognosis, they may eventually 
be incorporated into a weighted risk index, although it is un-
known whether they add information to existing indices of this 
type (such as the VACS Index and its successor, VACS 2.0) [16]. 
Furthermore, if NLR and PLR correlate with known inflamma-
tory pathways, they could be applied in large-scale research as 
a surrogate for less widely available biomarkers [16]. There has 
been substantial interest in inflammatory biomarkers in HIV, 
including interleukin (IL)-6, a marker of systemic inflammation 
and neutrophil activation, D-dimer, a marker of altered coagu-
lation activity, and soluble CD-14 (sCD-14), a marker of mono-
cyte activation [3, 17, 18].
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Table 1. Characteristics of Veterans Randomly Selected From VACS 2.0 Measurements Between 2000 and 2012, With NLR and PLR Measured Within 180 
Days of VACS 2.0, and Receiving ART for ≥1 Year (If HIV+)a
Measurement or Characteristic Overall HIV−/HCV− HIV+/HCV− HIV−/HCV+ HIV+/HCV+
N 89 786 47 570 11 881 8955 3713
Demographics      
Age (years) 52.9 ± 10.4 52.4 ± 10.4 51.5 ± 11.1 53.5 ± 6.2 54.0 ± 6.9
Male sex (%) 97.3 97.0 97.1 98.9 98.6
Race (%)      
 White 39.7 39.6 43.3 29.2 25.9
 Black 48.5 48.0 45.5 61.1 62.6
 Hispanic 8.8 9.8 7.2 8.6 9.5
 Other 3.0 2.7 4.0 1.2 2.1
BMI (kg/m2) 28.1 (24.5–32.2) 29.2 (25.6–33.4) 25.7 (22.9–29.1) 27.1 (23.9–30.8) 24.5 (21.8–27.6)
Prevalent Comorbidities
 CAD 14.3 15.3 9.8 12.4 9.5
 CHF 4.9 5.0 3.5 4.7 4.9
 BMI >30 33.5 39.2 19.8 27.0 12.9
 Alcohol abuse or dependence 26.0 24.4 20.4 52.7 47.8
 Alcohol-related complications 2.2 1.8 0.8 7.1 3.0
 Cirrhosis 2.1 1.0 0.9 9.3 7.6
 Diabetes mellitus 21.7 23.9 11.7 23.7 15.2
 COPD 15.2 15.0 13.4 17.7 20.2
 Cancer 3.2 3.0 4.1 2.6 2.8
CD4 (cells/mm3)      
 ≥500 40.6 -- 43.5 -- 30.8
 350–499 21.5 -- 21.3 -- 22.8
 300–349 21.1 -- 19.9 -- 25.3
 100–299 9.5 -- 8.5 -- 12.3
 50–99 3.4 -- 3.0 -- 4.6
 <50 4.0 -- 3.8 -- 4.3
HIV-1 RNA (copies/mL)
 ≤500 90.0 -- 82.8 -- 76.2
 500–10 000 14.6 -- 13.3 -- 18.4
 ≥10 000 4.4 -- 3.9 -- 5.4
Hemoglobin (g/dL)     
 ≥14 60.4 63.0 56.5 55.9 42.6
 12–13.9 29.2 28.6 31.3 29.3 35.1
 10–11.9 8.1 6.6 9.3 11.5 17.1
 <10 2.3 1.8 2.9 3.3 5.3
FIB-4      
 <1.45 68.4 76.1 65.8 41.1 27.6
 1.45–3.25 25.9 21.1 29.8 39.9 45.6
 >3.25 5.8 2.8 4.5 19.1 26.8
eGFR (mL/min per 1.73 m2)     
 ≥60 90.3 91.0 90.0 90.5 86.9
 45–59.9 5.5 5.2 6.2 3.9 6.0
 30–44.9 2.0 1.9 1.8 1.9 2.3
 <30 2.2 1.9 2.1 3.7 4.7
VACS Index 2.0 34 (26–45) 30 (24–37) 46 (36–58) 42 (36–51) 65 (54–79)
Died (%)      
 Within 180 days 3.7 2.4 4.1 5.0 8.4
 No 83.6 88.1 83.7 76.7 66.4
 After 180 days 12.7 9.6 12.3 18.3 25.2
HD (%)      
 Pre-existing (within 180 days) 2.9 1.9 2.2 8.7 9.0
 No 95.9 97.5 97.0 87.1 86.4
 Yes 1.2 0.7 0.8 4.2 4.6
White blood cells (×103/µL) 5.2 (4.6–8.3) 6.8 (5.5–8.6) 5.5 (4.4–7.0) 6.4 (4.8–8.3) 5.0 (3.8–6.6)
Neutrophils (×103/µL) 3.8 (2.7–5.2) 4.0 (2.9–5.5) 2.9 (2.1–4.1) 3.4 (2.3–5.0) 2.5 (1.7–3.8)
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We sought to elucidate the importance of NLR and PLR in 
patients with HIV on ART, with or without HCV coinfection. 
Our primary aim was to assess the prognostic significance of 
NLR and PLR, with respect to both mortality and hepatic de-
compensation (HD). Of particular interest was whether these 
markers improve discrimination of the VACS Index 2.0, a val-
idated risk index. Our second aim was to further investigate the 
relationship between NLR, PLR, and 3 alternative inflammatory 
biomarkers (IL-6, D-dimer, and sCD-14).
METHODS
We analyzed data from the Veterans Aging Cohort Study 
(VACS), a prospective longitudinal observational study of 
HIV-infected veterans that includes age, race, and site-matched 
HIV-negative veterans in care as controls [19]. The institutional 
review boards associated with participating VA sites and the co-
ordinating center approved the VACS. We randomly selected a 
visit date between 2002 to 2012, at which all results of interest 
Measurement or Characteristic Overall HIV−/HCV− HIV+/HCV− HIV−/HCV+ HIV+/HCV+
N 89 786 47 570 11 881 8955 3713
Platelets (×103/µL) 230 (189–276) 237 (199–281) 219 (180–263) 206 (157–258) 188 (140–240)
Lymphocytes (×103/µL) 1.9 (1.4–2.4) 1.9 (1.5–2.4) 1.8 (1.3–2.3) 1.9 (1.4–2.5) 1.6 (1.1–2.2)
NLR 2.0 (1.4–3.0) 2.1 (1.5–3.1) 1.7 (1.1–2.5) 1.7 (1.1–2.7) 1.6 (1.0–2.6)
PLR 122 (92–165) 125 (95–166) 122 (92–169) 104 (75–147) 113 (79–166)
Albumin (g/dL) 4.1 (3.8–4.4) 4.1 (3.9–4.4) 4.1 (3.8–4.4) 3.9 (3.6–4.2) 3.8 (3.4–4.1)
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; CAD, coronary artery disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; eGFR, esti-
mated glomerular filtration rate; HCV, hepatitis C virus; HD, hepatic decompensation; HIV, human immunodeficiency virus; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte 
ratio; RNA, ribonucleic acid; VACS, Veterans Aging Cohort Study.
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Figure 1. Hazard ratios for all-cause mortality associated with neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR). Levels defined by equal numbers 
of deaths. Error bars represent 95% confidence intervals. A and C are age-adjusted; B and D are adjusted for Veterans Aging Cohort Study (VACS) 2.0. A and B analyze NLR 
as an independent variable; C and D analyze PLR as an independent variable. HCV, hepatitis C virus; HIV, human immunodeficiency virus.
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were available (allowing values to carry forward 180 days); par-
ticipants with HIV had received at least 1 year of ART therapy. 
We assessed whether NLR and PLR added prognostic informa-
tion to the VACS Index 2.0 using multivariate adjustment. 
VACS 2.0 is a validated risk score incorporating age, CD4 count, 
HIV-1 ribonucleic acid (RNA), hemoglobin, FIB-4 (a com-
posite marker of liver fibrosis), estimated glomerular filtration 
rate, HCV coinfection, body mass index, albumin, and white 
blood cell count [20–22].
Active HCV infection was defined as (1) a positive HCV 
RNA, (2) a positive HCV genotype, or (3) 1 inpatient or 2 out-
patient HCV International Classification of Diseases, Ninth 
Revision (ICD-9) codes. Hepatitis C virus-negative status was 
defined as a negative HCV antibody test. All other patients were 
considered to have unknown HCV status. Those with positive 
HCV status at any timepoint during follow-up were classified as 
HCV positive.
Primary endpoints were mortality and HD. Death dates 
were determined from the VA vital status file, which com-
bines information from inpatient mortality, social security 
data, and national death benefits data; this method has been 
shown to provide excellent mortality ascertainment [23]. 
Hepatic decompensation was defined by ascites, sponta-
neous bacterial peritonitis, or esophageal varices; 1 inpatient 













Covariates in Model C-statistic AIC C-statistic AIC C-statistic AIC C-statistic AIC C-statistic AIC
VACS Index 2.0 0.758 247 201 0.773 92 309 0.784 25 254 0.725 28 035 0.735 14 189
VACS 2.0, NLR 0.766 246 270 0.778 92 150 0.786 25 227 0.732 27 997 0.738 14 183
VACS 2.0, PLR 0.764 246 825 0.779 92 143 0.787 25 239 0.728 28 018 0.736 14 193
VACS 2.0, NLR, PLR 0.767 246 157 0.780 92 094 0.788 25 217 0.735 27 976 0.738 14 188
Abbreviations: AIC, Akaike’s information criterion; HCV, hepatitis C virus; HD, hepatic decompensation; HIV, human immunodeficiency virus; NLR, neutrophil-to-lymphocyte ratio; PLR, 
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Figure 2. Hazard ratios for hepatic decompensation (HD) associated with neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR). Levels defined by 
equal numbers of HD events. Error bars represent 95% confidence intervals. A and C are age-adjusted; B and D are adjusted for Veterans Aging Cohort Study (VACS) 2.0. A and 
B analyze NLR as an independent variable; C and D analyze PLR as an independent variable. HCV, hepatitis C virus; HIV, human immunodeficiency virus.
NLR and PLR in HIV/HCV • ofid • 5
or 2 outpatient ICD-9 codes for any of these conditions were 
required.
We created a separate dataset using the VACS Biomarker 
Cohort (VACS BC) substudy to query associations between 
NLR, PLR, and other inflammatory biomarkers. Interleukin-6, 
sCD-14, and D-dimer were measured in banked specimens 
from blood drawn between 2005 and 2007. Assay methods have 
been previously described [8]. Patients with HIV in our subset 
of VACS BC had also received at least 1 year of ART. To ana-
lyze associations between NLR, PLR, and these biomarkers, we 
used NLR and PLR values closest to blood draw date (within 
90 days).
Statistical Analysis
Mortality was assessed at the first of 5  years of follow-up or 
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Figure 3. Forest plot of C-statistics (death outcome). Center dots represent Harrell’s c; whiskers represent 95% confidence intervals. Left column denotes subgroup; 
second column indicates covariates in each model. Covariates include categorical neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) and continuous 
Veterans Aging Cohort Study (VACS) 2.0. Overall cohort includes individuals without documentation of hepatitis C virus (HCV) status. HIV, human immunodeficiency virus. 
Table 3. Model Fit and Discrimination for Endpoint of Hepatic Decompensation
Endpoint: HD











 C-statistic AIC C-statistic AIC C-statistic AIC C-statistic AIC C-statistic AIC
VACS Index 2.0 0.801 23 452 0.778 6808 0.707 1704 0.765 6329 0.766 2541
VACS 2.0, NLR 0.802 23 449 0.786 6798 0.713 1709 0.764 6322 0.767 2545
VACS 2.0, PLR 0.803 23 294 0.791 6785 0.705 1701 0.769 6279 0.778 2531
VACS 2.0, NLR, PLR 0.805 23 247 0.793 6778 0.715 1705 0.776 6256 0.782 2533
Abbreviations: AIC, Akaike’s information criterion; HCV, hepatitis C virus; HD, hepatic decompensation; HIV, human immunodeficiency virus; NLR, neutrophil-to-lymphocyte ratio; PLR, 
platelet-to-lymphocyte ratio; VACS, Veterans Aging Cohort Study.
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determined at the first of 5 years of follow-up, the last date of 
care at a Veteran’s Administration, or September 30, 2015, due 
to changes in ICD coding after this date. We analyzed mortality 
and HD risk using Cox regression. Initial models assessing NLR 
and PLR as covariates were age-adjusted. We then adjusted for 
VACS 2.0 to evaluate whether NLR and PLR added prognostic 
information. Neutrophil-to-lymphocyte ratio and PLR were 
analyzed as categorical covariates using 5 levels. For mortality, 
these levels were defined to have equal number of deaths in 
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Figure 4. Forest plot of C-statistics (hepatic decompensation outcome). Center dots represent Harrell’s c; whiskers represent 95% confidence intervals. Left column denotes 
subgroup; second column indicates covariates in each model. Covariates include categorical categorical neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio 
(PLR) and continuous Veterans Aging Cohort Study (VACS) 2.0. Overall cohort includes individuals without documentation of HCV status.











Biomarker 1 Biomarker 2 r P Value r P Value r P Value r P Value r P Value
IL-6            
 NLR 0.15 <.0001 0.11 .05 0.22 .02 0.21 <.0001 0.21 <.0001
 PLR 0.049 .06 0.08 .14 0.06 .55 0.08 .07 0.05 .31
sCD-14            
 NLR 0.095 .0002 0.11 .04 0.17 .07 0.15 .001 0.13 .01
 PLR 0.055 .03 0.14 .01 −0.14 .12 0.10 .02 0.03 .51
D-dimer            
 NLR 0.12 <.0001 0.05 .36 0.27 .003 0.08 .09 0.11 .01
 PLR 0.12 <.0001 0.07 .21 0.08 .36 0.14 .001 0.03 .51
Abbreviations: IL-6, interleukin-6; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; sCD-14, soluble CD-14; VACS, Veterans Aging Cohort Study.
aCorrelations are Spearman’s rho.
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events. We stratified patients into 4 strata by HIV/HCV infec-
tion status for most analyses. The NLR or PLR level with the 
lowest age-adjusted association in HIV/HCV-coinfected pa-
tients was selected as the referent in each analysis. Patients ex-
periencing the endpoint within 180  days of the random visit 
date were excluded to avoid undue influence of imminent 
events that might have prompted ordering of a particular test. 
Given the association between NLR, PLR, and mortality in pa-
tients with cancer, we performed a sensitivity analysis excluding 
patients with malignancy.
We determined discrimination of combinations of covariates 
using Harrell’s c, with 95% confidence intervals (CIs) from the 
somersd package in Stata. Model fit was assessed using Akaike’s 
information criterion (AIC). In the VACS BC, we assessed the 
association between NLR, PLR and IL-6, D-dimer and sCD-14, 
using Spearman’s rank correlation.
Statistical significance was defined as a 2-tailed P  <  .05. 
Statistical analysis was performed in SAS version 9.4 (SAS 
Institute, Cary, NC) and Stata version 14 (StataCorp, College 
Station, TX).
RESULTS
Our sample included 89 786 veterans, 72 119 of whom had con-
firmed HCV status. The most common reason for a missing 
HCV status was lack of testing. The components of the NLR 
and PLR were distributed differently among strata defined by 
HCV and HIV infection, although frank thrombocytopenia, 
neutropenia, and leukopenia were uncommon (Table 1). As 
expected, HIV−/HCV− patients had the highest median levels 
of platelets, lymphocytes, and neutrophils. By contrast, HCV 
and HIV infection were each associated with decreased platelet 
and neutrophil count, with a synergistic effect in coinfection. 
Human immunodeficiency virus infection was associated with 
decreased lymphocyte counts. Consistent with these findings, 
NLR was overall lower in patients with HIV than those without. 
Likewise, PLR was lower in patients with HCV compared with 
those without.
Associations With Mortality
Over 5  years, 14  737 patients died, with 77% of these deaths 
occurring at least 180 days after the random visit date (Table 1, 
Supplementary Table 1). Of the deaths occurring after 180 days, 
8582 were included in analysis of the relationship between 
NLR, PLR, and mortality; those that were excluded lacked doc-
umentation of HCV status. Adjusting only for age, we found a 
J-shaped relationship between PLR and mortality and a more 
linear relationship between NLR and mortality (Figure 1, 
Supplementary Table 2). After adjustment for VACS 2.0, NLR 
remained associated with mortality. The association between 
mortality and NLR or PLR was similar across strata by HIV and 
HCV status for lower values of NLR or PLR, although hazard 
ratios (HRs) tended to be higher for uninfected controls than 
for patients with HIV and HCV among higher levels of NLR or 
PLR (Figure 1, Supplementary Table 2). Comparing highest to 
lowest NLR level, the VACS Index 2.0-adjusted HR associated 
with high NLR was 1.7 for HIV−/HCV− (95% CI, 1.5–1.9) and 
1.3 for HIV+/HCV+ patients (95% CI, 1.1–1.6). A similar trend 
was observed for PLR, comparing highest to second PLR level 
(uninfected: HR = 1.8 [95% CI, 1.6–1.9], coinfected: HR = 1.2 
[95% CI, 0.98–1.5]). Sensitivity analysis excluding patients 
with a history of malignancy did not significantly alter these 
results (data not shown). Addition of NLR, PLR, or both to 
Cox models using VACS 2.0 did not improve discrimination or 
model fit; C-statistic improvements did not meet statistical sig-
nificance in any subgroup, although point estimates increased 
by 0.003–0.009 (Table 2, Figure 3).
Hepatic Decompensation
Hepatic decompensation occurred in 3727 patients, with 30% 
of these events occurring at least 180 days after NLR and PLR 
were measured (Table 1, Supplementary Table 3). Of the HD 
events occurring at least 180 days after cohort entry, 980 had 
documented HCV status and were therefore included in this 
analysis. Hepatic decompensation was more common among 
patients with HCV than without. Low PLR was a significant 
predictor of incident HD among all levels, with PLR in the 
lowest level conferring a VACS 2.0-adjusted HR of 2.1 (95% CI, 
1.3–3.4) among coinfected patients and 2.3 (95% CI, 1.6–3.5) 
among uninfected patients (Figure 2D). Platelet-to-lymphocyte 
ratio in the highest level also predicted HD in uninfected pa-
tients (HR = 1.9; 95% CI, 1.4–2.6), but not in any other stratum. 
Neutrophil-to-lymphocyte ratio was independently predictive 
of HD in uninfected patients only (Supplementary Table 4, 
Figure 2A and B). Addition of NLR, PLR, or both to the VACS 
2.0 model resulted in point estimate C-statistic increases of 
0.004 in the overall cohort and 0.016 among HIV+/HCV+ pa-
tients; however, these increases did not meet statistical signifi-
cance (Table 3, Figure 4).
Association With Other Biomarkers of Inflammation
In VACS BC (n = 1475) (Table 4, Supplementary Table 5), NLR 
was correlated with IL-6 (r = 0.15, P < .0001) but PLR was not 
(r = 0.049, P =  .06). Neutrophil-to-lymphocyte ratio and PLR 
were correlated with D-dimer (both r = 0.12, P < .0001). Soluble 
CD-14 was correlated with NLR (r = 0.10, P = .0002) and PLR 
(r = 0.06, P = .03). Patterns were similar across HIV/HCV strata.
DISCUSSION
The ideal role for NLR and PLR in research and practice has 
yet to be determined, despite numerous analyses demonstrating 
their prognostic relevance. In this analysis, we evaluated 2 pos-
sible applications: (1) incorporation into a risk index and (2) 
use as a surrogate for a pathway to end-organ disease (immune 
dysfunction and systemic inflammation) [16].
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We found modest differences in HRs associated with level 
of PLR and NLR across strata, most of which were attenuated 
after adjustment for VACS Index 2.0. In particular, individ-
uals with higher NLR or PLR seemed to be at greater rela-
tive mortality risk in age-adjusted analyses if they were HIV/
HCV-negative than their uninfected counterparts. This trend 
should be interpreted in light of overall higher death rate in 
HIV/HCV coinfection, independent of NLR or PLR; although 
a high NLR or PLR may be a slightly less ominous sign in an 
HIV/HCV-coinfected patient than an uninfected patient, the 
absolute 5-year mortality rate for coinfected patients with 
high NLR was 44% compared with 22% in uninfected patients, 
with a similar trend for high levels of PLR. This suggests that 
individuals in the highest levels of NLR and PLR were likely 
characterized by higher illness severity overall, but that this 
risk was mostly captured by components of the VACS Index, 
such as FIB-4 score.
Despite an independent association between NLR and PLR 
with mortality and HD, NLR and PLR failed to improve dis-
crimination when added to models containing VACS Index 
2.0. Because C-statistic changes can be relatively insensitive, 
it is possible that inflammatory state as measured by NLR and 
PLR may have an impact on outcome apart from the variables 
measured in the VACS Index 2.0. However, the lack of improve-
ment in discrimination suggests these markers lack additional 
prognostic value beyond existing indices, and thus their clinical 
utility remains unclear.
We observed statistically significant but very weak correl-
ations between most combinations of PLR and NLR with 
D-dimer, sCD-14, and IL-6. The strongest correlation was be-
tween IL-6 and NLR, which is plausible given the documented 
role of IL-6 in neutrophil differentiation as well as known 
correlations between IL-6 and NLR in HCV monoinfection 
[24–26]. However, the use of these ratios as surrogates for 
systemic inflammation is somewhat confounded in HIV and 
HCV. Specific considerations include the effects of HIV on 
neutrophil and lymphocyte counts as well HIV-associated pan-
cytopenia. By adjusting for VACS 2.0, we have controlled for 
the expected effect of HIV severity (ie, CD4 count and HIV 
viral load) on mortality; however, VACS Index 2.0 was not 
designed to predict HD. The mortality-specific weighting of 
variables incorporated into VACS Index 2.0 to create a single 
number may oversimplify the relative independent risks of the 
component variables with respect to a different outcome (eg, 
FIB-4 score may be more strongly associated with HD than 
with mortality). In addition, liver fibrosis causes thrombocyto-
penia, and therefore it may affect the interpretation of PLR as 
a pure inflammatory marker. Based on weak correlations and 
possible confounding of interpretation of these ratios, it is un-
likely that NLR and PLR can reliably supplant IL-6, sCD-14, or 
D-dimer as measurements of clinically significant virally in-
duced inflammation.
Limitations of this analysis include its retrospective nature. 
In particular, although we found an association between NLR, 
PLR, and outcomes independent of VACS Index, our analysis 
does not rule out residual confounding, such as the possibility 
that NLR and PLR may reflect by additional comorbidities 
or clinical factors not accounted for in the VACS Index. Our 
dataset included a large number of deaths but fewer HD events, 
which limits the power of analyses using HD as an outcome. 
Furthermore, the use of NLR and PLR as biomarkers for HD 
risk in patients with versus without HCV is limited by the dif-
ferent biological pathways that may lead to HD in HCV-related 
versus nonrelated liver disease. Our data include participants 
in care between 2000 and 2012, with outcomes out to 2015 and 
2016; it is possible that the increasing number of patients with 
HCV and sustained viral response may affect the interpretation 
of NLR and PLR in HCV. Although the exclusion of patients 
who experienced endpoints within 180 days may introduce bias, 
sensitivity analyses including events occurring within 180 days 
of cohort entry found no substantive differences. Finally, we 
tested correlation between NLR and PLR with IL-6, soluble 
CD-14, and D-dimer, although many additional inflammatory 
biomarkers exist. Neutrophil-to-lymphocyte ratio and PLR may 
be more strongly correlated with other biomarkers.
CONCLUSIONS
Both NLR and PLR were statistically independent of the VACS 
Index 2.0 for mortality prediction, as was PLR for the prediction 
of HD. Both ratios demonstrated moderate correlation with in-
flammatory biomarkers. However, neither NLR nor PLR added 
meaningfully to the discriminative ability of a validated risk 
index for mortality. Further research may be indicated to deter-
mine the usefulness of NLR and PLR in (1) prognostication for 
liver fibrosis and hepatocellular carcinoma, especially in HIV/
HCV-coinfected patients and (2) surrogacy for alternative in-
flammatory biomarkers.
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